PUMA BIOTECHNOLOGY financials
$9.78−0.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M | $27.7M | — |
| Gross profit | $170.2M | $166.1M | $173.0M | $172.9M | $189.5M | $185.7M | $235.4M | $216.4M | $22.1M | — |
| Gross margin | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.9% | — |
| Operating income | $37.3M | $31.0M | $32.6M | $11.3M | $1.3M | -$30.4M | -$39.0M | -$103.7M | -$292.4M | -$276.6M |
| Net income | $31.1M | $30.3M | $21.6M | $2.0K | -$29.1M | -$60.0M | -$75.6M | -$113.6M | -$292.0M | -$276.0M |
| Net margin | 13.6% | 13.1% | 9.2% | 0.0% | −11.5% | −26.7% | −27.8% | −45.3% | −1054.6% | — |
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | $-1.95 | $-2.99 | $-7.85 | $-8.29 |
| EBITDA | $48.2M | $42.5M | $44.2M | $33.6M | $12.6M | -$20.4M | -$31.0M | -$87.3M | -$289.6M | -$272.4M |
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M | $773.0K | $22.4M | -$24.5M | -$172.4M | -$145.8M |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M | $727.0K | $22.1M | -$25.1M | -$172.8M | -$153.1M |
| Diluted shares | 50.7M | 49.1M | 47.6M | 44.9M | 40.6M | 39.6M | 38.8M | 37.9M | 37.2M | 33.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M | $85.3M |
| Short-term investments | $67.9M | $31.7M | $11.4M | $4.9M | $19.0M | $8.1M |
| Total debt | $22.5M | $67.0M | $99.7M | $98.3M | $97.1M | $98.3M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M | $244.2M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M | $250.2M |
| Shareholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | -$2.4M | -$6.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology